# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-21-054580
Filing Date
2021-04-26
Accepted
2021-04-23 18:02:31
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | tm2113795d2_defa14a.htm | DEFA14A | 22028
2 | GRAPHIC | image_001.jpg | GRAPHIC | 560898
3 | GRAPHIC | image_002.jpg | GRAPHIC | 241030
| Complete submission text file | 0001104659-21-054580.txt |  | 1128223

Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33958 | Film No.: 21850871
SIC: 2834 Pharmaceutical Preparations